廣告
香港股市 已收市

  • 恒指

    16,224.14
    -161.73 (-0.99%)
     

  • 國指

    5,746.61
    -57.25 (-0.99%)
     

  • 上證綜指

    3,065.26
    -8.96 (-0.29%)
     

  • 滬深300

    3,541.66
    -28.14 (-0.79%)
     

  • 美元

    7.8332
    +0.0020 (+0.03%)
     

  • 人民幣

    0.9238
    +0.0001 (+0.01%)
     

  • 道指

    37,987.27
    +211.89 (+0.56%)
     

  • 標普 500

    4,983.98
    -27.14 (-0.54%)
     

  • 納指

    15,376.10
    -225.40 (-1.44%)
     

  • 日圓

    0.0504
    +0.0000 (+0.04%)
     

  • 歐元

    8.3463
    +0.0119 (+0.14%)
     

  • 英鎊

    9.7040
    -0.0350 (-0.36%)
     

  • 紐約期油

    83.48
    +0.75 (+0.91%)
     

  • 金價

    2,413.20
    +15.20 (+0.63%)
     

  • Bitcoin

    64,249.34
    +711.30 (+1.12%)
     

  • CMC Crypto 200

    1,376.63
    +64.01 (+4.88%)
     

Fate Therapeutics to Present at Upcoming June Investor Conferences

Fate Therapeutics, Inc.
·2 分鐘文章
Fate Therapeutics, Inc.
Fate Therapeutics, Inc.

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:

  • 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 3:30 PM ET in New York, New York

  • 44th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 13, 2023 at 5:00 PM ET in Dana Point, California

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

廣告

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens, and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com